Trademark: 79387728
Word

Status
Pending
Status Code
661
Status Date
Friday, September 13, 2024
Serial Number
79387728
Mark Type
2
Filing Date
Thursday, November 2, 2023

Trademark Owner History

Classifications
5 Medicines for human purposes, namely, medicines for the treatment of degenerative disease, motor neuron disease; medicines for human purposes, namely, medicines for the treatment of epilepsy; medicines for human purposes, namely, medicines for the treatment of macular degeneration; medicines for human purposes, namely, medicines for alleviating constipation; medicines for human purposes, namely, medicines for the treatment of cardiovascular disease, coronary heart disease, angina pectoris, myocarditis, cardiac arrhythmia, tumors, infectious diseases, autoimmune disease, blood disease, mental illness, ophthalmic disorders, metabolic diseases and disorders in the nature of diabetes, kidney diseases, osteoporosis; antiviral medicines; anesthetics; antibiotics and bacterial poisons; medicines for human purposes, namely, biological products, prepared by using biological materials in the nature of microorganisms, cells, and various animal and human tissues and liquids, obtained by biological techniques, namely, genetic engineering, cell engineering, protein engineering, fermentation engineering for the treatment of central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, antipyretic and analgesic purposes, non-steroidal anti-inflammatory purposes, infectious diseases, autoimmune diseases, anti-tumor purposes, hypoglycemic and diuretic purposes, vitamin and hormonal purposes; medicines for human purposes, namely, parenteral nutrition supplements; Transplants, namely, bone graft materials derived from human tissue, processed human donor skin for the replacement of soft tissue, surgical mesh comprised primarily of living tissue, ex vivo cells, namely, immune cells, red blood cells, t cells, nk cells, islet cells; collagen for medical purposes; immunostimulants; nutraceutical preparations for therapeutic or medical purposes for use in the treatment of degenerative diseases; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment and prevention of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for reducing cholesterol; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases and arthritis; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparation for treating microbial diseases, namely, antibiotics; pharmaceutical preparations for the treatment of mental illness and ophthalmic disease; pharmaceutical preparations for contrast agent, infectious disease, blood disease and kidney disease; pharmaceutical preparations containing chemical drugs and biological products for the prevention and treatment of central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, infectious diseases, autoimmune diseases; pharmaceutical preparations containing chemical drugs and biological products for antipyretic and analgesic purposes, non-steroidal anti-inflammatory purposes, anti-tumor purposes, hypoglycemic and diuretic purposes, vitamin and hormonal purposes and parenteral nutrition purposes; chemico-pharmaceutical preparations for the treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases and infectious diseases; chemico-pharmaceutical preparations for relief from asthma and coughs; chemico-pharmaceutical preparations for parenteral nutrition purposes, antipyretic and analgesic purposes, non-steroidal anti-inflammatory purpose, anti-tumor purposes, hypoglycemic and diuretic purposes, vitamin and hormonal purposes; pharmaceutical preparations for use in tissue and organ transplantation, pharmaceutical preparations for human use for the prevention of solid organ transplant rejection, pharmaceutical preparations for transplantation and transplant-related conditions affecting the kidney, bone graft materials derived from human tissue, processed human donor skin for the replacement of soft tissue, surgical mesh comprised primarily of living tissue, ex vivo cells, namely, immune cells, red blood cells, t cells, nk cells, islet cells; vaccines; drugs for medical purposes for the treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, infectious diseases, autoimmune disease; drugs for medical purposes for relief from asthma and coughs; drugs for medical purposes, namely, parenteral nutrition purposes, antipyretic and analgesic purposes, nonsteroidal antiinflammatory purpose, anti-tumor purposes, hypoglycemic and diuretic purposes, vitamin and hormonal purposes; serums for medical purposes for treatment of skin; opotherapy preparations; blood plasma; biological preparations for medical purposes, namely, antitoxic sera, antitoxins, toxoids, toxins, human and veterinary vaccines, and for use in cell cultures; biological preparations for veterinary purposes, namely, veterinary pharmaceutical preparations for respiratory and reproductive diseases in cattle, veterinary pharmaceutical preparations for the treatment of arthritis, muscle soreness and sprains, veterinary pharmaceutical preparations for the treatment of bacterial infections in dogs, veterinary pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections, topical infections; veterinary pharmaceutical preparations for the treatment of infectious diseases, namely, swine dysentery, bacterial enteritis, bluecomb, pneumonia; veterinary pharmaceutical preparations for the treatment of vitamin deficiencies; veterinary preparations for treatment of intestinal bacteria; biochemical preparations for veterinary purposes for the treatment of tumors; enzymes for medical purposes; enzyme preparations for medical purposes; diagnostic biomarker reagents for medical purposes; medicines for veterinary purposes, namely, laxatives for veterinary purposes, pain relief medication for veterinary purposes, suppositories for veterinary purposes; stem cells for veterinary purposes; biological tissue cultures for veterinary purposes
44 Medical clinic services; telemedicine services; therapy services, namely, cognitive therapy services, voice and speech therapy services, insomnia therapy services, physiotherapy, psychological counseling services, psychotherapy services, respiratory therapy services, drug rehabilitation counseling services, addiction treatment services; stem cell therapy services; health counselling; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; convalescent home services; advisory services relating to health; services of a psychologist; massage; rental of sanitary installations
42 Product quality testing; chemical research; bacteriological research; biological research; Medical and Scientific research, namely, conducting clinical trials for others; medical research; biological cloning services; stem cell research services; medical research laboratory services; genetic testing for scientific research purposes
The non-Latin characters in the mark transliterate to "SHI ZE" and this means "SCHOLAR" and "BENEFIT" respectively in English, but together have no meaning in a foreign language.

Trademark Events
Jan 19, 2024
New Application Office Supplied Data Entered
Jun 13, 2024
Assigned To Examiner
Jun 21, 2024
Non-Final Action Written
Jan 18, 2024
Sn Assigned For Sect 66a Appl From Ib
Jan 23, 2024
Application Filing Receipt Mailed
Jun 22, 2024
Non-Final Action (Ib Refusal) Prepared For Review
Sep 13, 2024
Teas/Email Correspondence Entered
Sep 13, 2024
Correspondence Received In Law Office
Sep 13, 2024
Teas Response To Office Action Received
Aug 4, 2024
Refusal Processed By Ib
Jul 15, 2024
Non-Final Action Mailed - Refusal Sent To Ib
Jul 15, 2024
Refusal Processed By Mpu

Trademark Alertz updated from USPTO on 2030-01-24